PeptiDream Inc. (TYO:4587)
Japan · Delayed Price · Currency is JPY | Market Cap | 191.37B -24.3% |
| Revenue (ttm) | 18.52B -60.3% |
| Net Income | -3.75B |
| EPS | -28.99 |
| Shares Out | 129.21M |
| PE Ratio | n/a |
| Forward PE | 11.63 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,488,000 |
| Average Volume | 1,257,280 |
| Open | 1,394.00 |
| Previous Close | 1,410.50 |
| Day's Range | 1,381.00 - 1,481.00 |
| 52-Week Range | 1,310.00 - 2,365.50 |
| Beta | 0.04 |
| RSI | 50.62 |
| Earnings Date | Feb 16, 2026 |
About PeptiDream
PeptiDream Inc., a biopharmaceutical company, engages in the discovery and development of constrained peptides, small molecules, and peptide-drug conjugate therapeutics. The company develops its products based on its Peptide Discovery Platform System, a drug finding platform that enables the production of non-standard peptide libraries for the identification of potent and selective macrocyclic peptide candidates, which then can be developed into peptide-based, small molecule-based, peptide-drug conjugate, and multi-functional peptide conjugates... [Read more]
Financial Performance
Financial StatementsNews
Curium Group, PeptiDream and PDRadiopharma Enroll First Patient to Registrational Clinical Trial of Lu-PSMA-I&T for Prostate Cancer in Japan
BOSTON, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Curium Group today announced that together with PeptiDream Inc. and PDRadiopharma Inc., the first patient has been dosed in the companies' registrational clin...
PeptiDream Announces Promising Pre-Clinical Results of Proprietary Oral IL-17A and IL-17F Dual Inhibitor with Biologic-Like Efficacy for the Treatment of Psoriasis
KAWASAKI, Japan--(BUSINESS WIRE)-- #IL17--PeptiDream is advancing the oral IL-17a/ IL-17F dual inhibitor peptide program into IND-enabling studies, while exploring strategic partnerships.